The microphthalmia-associated transcription factor (MITF) is indispensable for the viability of melanocytic cells, is an oncogene in melanoma and has a cell type-specific expression pattern. As the modulation of MITF activity by direct chemical targeting remains a challenge, we assessed a panel of drugs for their ability to downregulate MITF expression or activity by targeting its upstream modulators. We found that the multi-kinase inhibitors midostaurin and sunitinib downregulate MITF protein levels. To identify the target molecules shared by both the drugs in melanocytic cells, a chemical proteomic approach was applied and AMP-activated kinase (AMPK) was identified as the relevant target for the observed phenotype. RNA interference and chemical inhibition of AMPK led to a decrease in MITF protein levels. Reduction of MITF protein levels was the result of proteasomal degradation, which was preceded by enhanced phosphorylation of MITF mediated by ERK. As expected, downregulation of MITF protein levels by AMPK inhibition was associated with decreased viability. Together, these results identify AMPK as an important regulator for the maintenance of MITF protein levels in melanocytic cells.
INTRODUCTION
The basic helix-loop-helix leucine zipper transcription factor, microphthalmia-associated transcription factor (MITF), has been shown to be a melanoma-specific oncogene in addition to a master regulator of melanocytes. 1 Most melanomas express MITF and a significant proportion of melanomas harbour an amplification of this gene. 1 In addition, two groups recently indentified a germline mutation in MITF that predisposes to melanoma. 2, 3 One of the transcriptional targets of MITF is the antiapoptotic protein Bcl-2, 4 thus explaining the dependence of both melanocytes and melanoma cells on MITF for survival. Recently, it was shown that MITF induces transcription of multiple genes involved in DNA replication, DNA damage repair and mitosis in melanoma cells. 5, 6 All these processes are a prerequisite for proper cell proliferation. Therefore, targeting MITF as a means of combatting melanoma is attractive. Therapeutic efforts to target this protein, however, are hindered by the fact that transcription factors lack a catalytic domain that can be targeted. Given that the expression and activity of MITF are tightly regulated, it should be possible to indirectly target MITF by interfering with its upstream modulators. Key established modulators of MITF are ERK and RSK, 7 members of the mitogenactivated protein kinase pathway that is hyperactivated in the majority of melanomas because of the presence of an oncogenic mutation in BRAF. 8 Activation of this pathway results in phospho-ERK-and phospho-RSK1-mediated phosphorylation of MITF at serine 73 and 409, respectively, inducing its transcriptional activity. 7, 9, 10 Phosphorylation of MITF at these sites is followed by its ubiquitination and proteasome-mediated degradation.
Thus, the activation of MITF is tightly coupled to subsequent degradation. Additional post-translational modifications of MITF include phosphorylation by GSK3b at serine 298 11 and sumoylation, 12, 13 both of which have been shown to modulate MITF activity.
The importance of a tight regulation of MITF protein levels is reflected by emerging evidence showing that the protein level of MITF dictates function, a concept formulated in the rheostat model of MITF function. 5, 14, 15 This model reconciles the, at first sight, paradoxical observation that MITF is of crucial importance in both differentiated melanocytes and melanoma cells. The model does so by postulating that high levels of MITF result in a differentiated phenotype, intermediate levels in a proliferative phenotype, low levels in a stem cell/invasive phenotype and complete absence in a senescent phenotype. 6, 16 Each state on the MITF rheostat is characterised by the expression of distinct molecular markers, for example, low MITF levels are associated with the expression of stem cell marker Oct-4; 17 intermediate levels of MITF with high expression of proliferation markers such as CDK2 and CDK4, 18 and cells highly expressing MITF are pigmented and express tyrosinase.
We hypothesised that drug-mediated inhibition of MITFactivating molecules could impair the viability of melanocytic cells and assessed a panel of different classes of drugs for their capacity to (indirectly) downregulate MITF. We observed that the multi-kinase inhibitors midostaurin and sunitinib, compounds with an overlapping target-spectrum, 19, 20 downregulated MITF protein levels. Subsequent chemical proteomic analysis of the cell-specific target molecules shared by both drugs led to the identification of AMP-activated kinase (AMPK) as a kinase important not only for the modulation of post-translational phosphorylation of MITF, but also for the maintenance of MITF protein levels in melanocytic cells. Figure 1a ) and its target gene Bcl-2 (Figure 1b) , 4 while co-expression of MITF induced Bcl-2 ( Figure 1b) . Importantly, the remaining low MITF protein levels in BRAF V600E expressing human melanocytes (Supplementary Figure S1a) We assessed a panel of 14 compounds that are either already approved by the US Food and Drug Administration or under clinical evaluation. Together, these compounds target a wide spectrum of signalling pathways. Most of the drugs used were kinase inhibitors (Supplementary Table S1 ). Initially, we screened for reversion of the phenotype induced by MITF in BRAF V600E /MITF melanocytes, that is, rescue of contact inhibition as indicated by the absence of foci formation. Next, we assessed whether the thus selected drug(s) also downregulated MITF protein levels. From this two-step procedure, the multi-kinase inhibitor midostaurin was identified as a drug that downregulates MITF protein levels. In support of this finding, sunitinib (a kinase inhibitor with an overlapping target spectrum 19, 20 ) also downregulated MITF protein levels (Figures 2a and b) .
RESULTS

Kinase
Midostaurin and sunitinib share kinase targets in melanocytic cells To ascertain which of the shared kinase(s) targeted by midostaurin and sunitinib is/are responsible for the maintenance of MITF protein levels in melanocytic cells, the target profile of each drug in BRAF V600E /MITF melanocytes was determined using a chemical proteomic approach. Analogues of both drugs were prepared, which allowed for immobilisation followed by affinity purification of drug-interacting proteins (Supplementary Figure S3) . In vitro kinase assays with the respective cognate targets confirmed retention of inhibitory activity for each analogue (Supplementary Table S2 ). Drug pull-downs with midostaurin and sunitinib were performed with lysates of BRAF V600E /MITF melanocytes and protein eluates analysed by gel-free one-dimensional liquid chromatography mass spectrometry (1D-LCMS). Of 42 kinases detected, in total, 12 and 11 kinase targets of midostaurin and sunitinib, respectively, were identified as the most prominent AMPK is a modulator of melanoma oncogene MITF V Borgdorff et al interactors, when target selection was based on a minimum protein sequence coverage of 10%. Seven of the targets were shared by both the drugs (Table 1, Supplementary Table S3 ). In addition to the gel-free one-dimensional liquid chromatography mass spectrometry experiments, a quantitative proteomic analysis of midostaurin-and sunitinib-enriched proteins was performed using isobaric tag for relative and absolute quantitation (iTRAQ) labelling combined with gel-free two-dimensional liquid chromatography mass spectrometry. With this approach, kinases equally enriched by both drugs and proteins preferentially targeted by either of the compounds (cutoff value: X2-fold enrichment) were detected. In total, 47 kinases were identified, of which 11 kinases were equally enriched by both the drugs ( Figure 3 and Supplementary Table S4 ). Comparison of the seven candidate kinases obtained from the one-dimensional liquid chromatography mass spectrometry analysis with the 11 candidate kinases obtained by iTRAQ combined with two-dimensional liquid chromatography mass spectrometry revealed two kinases that were identified by both approaches: AMPKa1 and AAK1. Given the identified role of AMPK in cancer biology, 21 this protein was selected for further validation experiments.
AMPK inhibition downregulates MITF protein levels First, we asked whether AMPK signalling is active in human melanocytic cells and performed western blot analysis of parental immortalised melanocytes, BRAF V600E and BRAF V600E /MITF melanocytes, as well as several melanoma cell lines using an antibody targeting acetyl coenzyme A carboxylase (ACC) phosphorylated at serine 79, a site uniquely targeted by AMPK. 22, 23 Parental immortalised human melanocytes showed low levels of pACC, whereas BRAF V600E melanocytes contained rather high levels of The Human Kinome Map was adapted with permission from Cell Signaling Technology (www.cellsignal.com). Kinases that were enriched more strongly with midostaurin than with sunitinib (by at least 2-fold) are depicted in brown, kinases equally enriched by both the drugs (between 0.5-and 2-fold) are represented by tan circles and kinases more strongly enriched with sunitinib than with midostaurin (by at least 2-fold) are shown in grey. Kinases that could not be quantitated by iTRAQ are displayed in white. The actual relative quantitative values are given in Supplementary Table S4. pACC (Figure 4a ), comparable to the levels observed in human melanoma cells WM983A, SK-Mel-5 and MALME-3M (Supplementary Figure S4a) . BRAF V600E /MITF melanocytes showed lower levels of pACC (Figure 4a, Supplementary Figure S4a) . These data show the AMPK pathway to be active in human melanocytic cells, both melanocytes and melanoma cells. To investigate the effect of AMPK inhibition on MITF protein expression, we performed western blot analysis and immunofluorescence with BRAF V600E /MITF melanocytes treated with compound C, a compound identified in a chemical library screen as a potent inhibitor of AMPK. 24 Compound C treatment resulted in an inhibition of AMPK activity (reflected by a decrease of pACC protein levels) along with a downregulation of MITF protein levels (Figures 4b and c) .
AMPK is a heterotrimeric protein consisting of an a-catalytic subunit (either AMPKa1 or AMPKa2) and a b-and g-regulatory subunit. 25 To further validate the results obtained by chemical inhibition, we performed RNA interference with the expression of AMPKa1 and AMPKa2 in BRAF AMPK inhibition induces phosphorylation of MITF followed by its degradation To dissect the mechanism underlying MITF downregulation upon AMPK inhibition, a time-course experiment was performed with compound C. MITF phosphorylation 9, 10 was induced by compound C within the first 4 h, followed by an almost complete loss of detectability after 24 h of treatment (Figure 6a) . At the latter timepoint we also observed a downregulation of MITF target gene Bcl-2. Downregulation of MITF could be prevented by pre-treatment with proteasome inhibitor MG132 (Figure 6b ). These data show that downregulation of MITF via AMPK inhibition is a consequence of proteasomal degradation and that, in agreement with a previous report, 10 degradation of MITF was preceded by increased phosphorylation (Figures 6a and b) .
MITF phosphorylation upon AMPK inhibition is dependent on active ERK Key kinases responsible for MITF phosphorylation are the mitogen-activated protein kinase pathway members ERK1/ ERK2. 7, 9, 10 To determine whether these molecules contribute to the initial induction of MITF phosphorylation upon AMPK inhibition with compound C, we performed a western blot analysis of phospho-ERK levels upon treatment of BRAF V600E /MITF melanocytes with compound C. As shown in Figure 6c , compound C induced phospho-ERK together with phosphorylated MITF. In addition, RNA interference with expression of AMPK using two independent siRNA sets targeting AMPKa1 and AMPKa2 resulted in an upregulation of pERK (Figure 6d ), further advocating a role for pERK in the regulation of MITF via ERK. Conversely, pre-and cotreatment with MEK1/MEK2 inhibitors U0126 or PD98059 interfered with the induction of phospho-ERK and (at least partially) prevented the induction of MITF phosphorylation by AMPK inhibition (Figure 6c ), substantiating the contribution of phospho-ERK in the phosphorylation of MITF upon AMPK inhibition. AMPK has been shown to activate protein phosphatase 2A 26 and to induce dual specificity phosphatases. 27 Both classes of phosphatases can dephosphorylate phospho-ERK. 28 Consistently, we observed an induction of pERK levels in BRAF V600E /MITF melanocytes upon treatment with okadaic acid (Supplementary Figure S6) , an established inhibitor of protein phosphatase 2A, which can also inhibit dual specificity phosphatases. 29 
DISCUSSION
The transcription factor MITF plays a crucial role in maintaining the viability of melanocytic cells, 1, 4, 6 and its essential function is restricted to cells of the melanocyte cell lineage, mast cells and osteoclasts. 30 Moreover, MITF is an oncogene in at least a subset of melanoma tumours. [1] [2] [3] Direct chemical targeting of MITF, however, remains a challenge because of the lack of a catalytic domain. An elegant indirect targeting approach in which MITF was targeted by interfering with mechanisms required for its expression has been shown to be successful. 31 Multiple histone deacetylase inhibitors reduced MITF expression in human melanoma cells both in vitro and in vivo when xenografted onto mice, thus suppressing melanoma cell proliferation both in vitro and in vivo. However, histone deacetylase inhibitors affect numerous additional proteins, thereby potentially inducing multiple unexpected and adverse effects when applied therapeutically. 31, 32 We aimed at identifying a drug with a narrower target spectrum that could still decrease MITF activity by targeting an upstream modulator of MITF. We found that both midostaurin and sunitinib (two multi-kinase inhibitors with a highly overlapping target spectrum) mediated downregulation of MITF in melanocytic cells. Using a chemical proteomic approach to deconvolute the targets of these drugs in melanocytes, we could show that AMPK is essential to maintain MITF protein levels in these cells. Consistently, AMPK has recently been identified as one of the targets of sunitinib in intact PC3 human prostate cancer cells and in cell-free kinase assays with AMPKa1-containing complexes immunoprecipitated from PC3 cells. 33 AMPK is an energy sensor of the cell that maintains cellular energy homeostasis by stimulating catabolic pathways upon an increase of the cellular AMP/ATP ratio. 25 Recent studies have shown that in melanomas harbouring a BRAF V600E mutation, AMPK activation is impaired because of the mitogen-activated protein kinase--dependent inactivation of AMPK's upstream activator LKB1. 34, 35 Our results show that, even in the context of an activating BRAF V600E mutation and an inactivating mutation in LKB1, AMPK still plays an important role in melanocytic cells as it may profoundly regulate MITF protein levels and activity. A possible explanation may be that AMPK can be activated not only by LKB1, but also by calmodulin-dependent protein kinase 2. [36] [37] [38] By sequence homology, calmodulin-dependent protein kinase 2 is the mammalian kinase closest to LKB1. 39 Although tissue-specific deletion has shown that LKB1 is the major activator of AMPK in several tissue types, calmodulin-dependent protein kinase 2 seems to be a key activator of AMPK in neurons and T cells. 39 Given that neurons and melanocytes are derived from the same progenitor cell population (both cell types stem from the neural crest), it is reasonable to assume that calmodulindependent protein kinase 2 could also be an important activator of AMPK in melanocytic cells. Furthermore, our data point towards a regulation of MITF protein levels by AMPK inhibition via the induction of ERK signalling, consistent with the recently demonstrated inhibition of ERK signalling by AMPK in cardiac fibroblasts. 40 Figure 7 schematically depicts how AMPK signalling may impact on MITF in melanocytic cells.
The link between AMPK and MITF may also be interesting in the light of the previously demonstrated relationship between LKB1 (an upstream activator of AMPK) and pigmentation. Patients with Peutz-Jeghers syndrome, a dominantly inherited disorder often caused by inactivating germline mutations in LKB1, present with melanocytic macules at the skin and the mucosa. 41 These data suggest that, in contrast to our observations, inactivation of the AMPK signalling pathway may rather result in the permanent activation of MITF. A likely explanation for this difference is the fact that salt-inducible kinase 2, an AMPK family member and also a target of LKB1, represses CREB-specific coactivator TORC1 (also called CRTC1), thereby interfering with CREB-induced MITF transcription. 42 In patients with Peutz-Jeghers syndrome, the failure to activate salt-inducible kinase 2 because of inactive LKB1 is expected to result in increased CREB-mediated MITF transcription, rather than in downregulation of MITF protein levels as described in our study. Together these data suggest that the AMPK family of proteins may have a dual impact on MITF expression. AMPK (family members) may inhibit MITF transcription via the repression of CREB-specific co-activator TORC1 on one hand, but maintain MITF protein expression on the other. The role of AMPK in tumorigenesis seems to be contextdependent. 21 It has been shown to inhibit mammalian target of rapamycin complex 1 (mTORC1), which is activated by the AKT signalling pathway. 25 Consistently, tumour growth of xenotransplanted human breast cancer cells in mice was suppressed by AMPK activator OSU-53 43 and a retrospective analysis of diabetes patients taking the anti-diabetic drug metformin, which activates AMPK, showed a significantly reduced risk for breast cancer. 44 In contrast, AMPK was shown to aid in the adaptation of tumour cells to a hypoxic environment and H-Ras-transformed AMPKa-null mouse embryonic fibroblasts formed much smaller tumours than wild-type mouse embryonic fibroblasts. 45 Furthermore, AMPK was found to be activated in human prostate cancer specimens and cell lines as indicated by increased expression of pACC compared to normal prostate tissue, and inhibition of AMPK in human prostate cancer cells decreased cellular proliferation. 46 In melanoma, only a limited amount of data are available on AMPK and tumour biology. Recently, Tomic et al. 47 showed that metformin has an anti-proliferative effect on human melanoma cells by stimulating autophagy and apoptosis and Janjetovic et al. 48 observed similar effects in B16 mouse melanoma cells. In both the experimental settings, however, metformin-induced anti-tumour effects were mostly independent of AMPK. In agreement with studies showing that MITF is crucial for the viability of melanocytic cells, 1, 4, 6 we found that MITF downregulation through inhibition of AMPK signalling decreased cell viability in a dose-dependent manner in BRAF V600E /MITF immortalised melanocytes. To our knowledge, this is the first study showing that AMPK inhibition interferes with MITF protein expression and melanocytic cell viability. Although we cannot formally exclude activation of the mTOR pathway upon AMPK inhibition in our system, our results show that these effects are not sufficient to prevent the reduction of viability in human melanoma cells. These data suggest that AMPK inhibition as a potential therapeutic strategy for melanoma treatment deserves further clinical exploration.
MATERIALS AND METHODS
Antibodies and chemical reagents
Antibodies raised against the following antigens were used: MITF (C5) (sc-56725), HA (sc-7392), Bcl-2 (sc-509), GAPDH (sc-25778) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); HA (2367); AMPKa (2532), AMPKa1 (2795) (Cell Signaling Technology, Danvers, MA, USA); MITF (C5) (Ab-1, MS-771) (Labvision/Neomarkers, Fremont, CA, USA); MITF (C5) (ab12039) (Abcam, Cambridge, UK); a-tubulin (CP06) (Calbiochem, Gibbstown, NJ, USA); pACC (Ser79) (Millipore, Billerica, MA, USA); HRP-conjugated secondary antibody raised against mouse and rabbit IgG (Bio-Rad, Hercules, CA, USA). Midostaurin and staurosporin were purchased from LC Laboratories (Woburn, MA, USA); sunitinib was purchased from LC Laboratories and Selleck Chemicals (Houston, TX, USA); compound C was purchased from Tocris Bioscience (Bristol, UK); U0126 was purchased from Selleck Chemicals; PD98059 and okadaic acid were purchased from Calbiochem; iodoacetamide, dithiothreitol, 1 M triethylammonium bicarbonate and formic acid were purchased from Sigma-Aldrich (St Louis, MO, USA); modified porcine trypsin was purchased from Promega Corp. (Madison, WI, USA).
Cell lines
Primary human melanocytes immortalised by transduction with hTERT, p53DD, CDK(R24C) (primary melanocytes/hTERT/CDK4(R24C)/p53DD) with and without ectopically expressed BRAF V600E and HA-MITF have been described earlier. 1 Drug screen
All compounds used in the screen were dissolved in DMSO at a concentration of 10 mM. Cells were plated at a density of 3500 cells per well of a 96-well plate in 100 ml media. Twenty-four hours after plating, all cells were adherent and drugs, prediluted in media, were added. Final cellular DMSO concentration was 0.1% in every well. Each compound was assayed at nine different concentrations ranging from 20 mM to 0.3 nM in triplicate. At 24, 48 and 72 h after drug addition, cell growth was monitored for the presence/absence of contact inhibition and foci formation.
Chemical proteomics
Immobilisation and affinity purification. c-Sunitinib was synthesised by Gateway Pharma (Freeland, UK). c-Midostaurin was synthesised internally by amidification of staurosporine with N-Boc-protected m-aminomethylbenzoic acid in the presence of HATU and diisopropylethylamine and subsequent deprotection with trifluoroacetic acid (all from Sigma-Aldrich). The coupleable drug analogues were immobilised on NHS-activated Sepharose 4 Fast Flow resin (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) as described previously. 49 Affinity chromatography and elution were performed in duplicate for each drug and cell line with a minimum of 10 mg total protein, as reported previously. 50 Competition experiments were performed by incubation of a 10-mg aliquot of each cell lysate with the c-midostaurin drug affinity matrix in the presence of 20 mM unmodified midostaurin.
Kinase inhibition analysis. In vitro kinase inhibition assays were performed on the Millipore KinaseProfiler platform. c-Midostaurin was compared to midostaurin for inhibition of FLT3 (at 0.01, 0.1 and 1 mM), c-sunitinib was compared to sunitinib for inhibition of PDGFRa (at 0.1, 1 and 10 mM).
Solution tryptic digestion and peptide purification. Using the c-midostaurin and c-sunitinib affinity matrices, the enriched protein eluates obtained from BRAF V600E and BRAF
V600E
/MITF melanocytes, respectively, were reduced with dithiothreitol, cysteine residues alkylated by incubation with iodoacetamide and the samples digested with modified porcine trypsin. Three percent (and multiples thereof) of the digested eluates were purified and concentrated by C18 reversed-phase material 51 for subsequent duplicate analysis by one-dimensional gel-free liquid chromatography mass spectrometry.
iTRAQ-labelling and reversed-phase peptide fractionation. The remaining peptides were individually derivatised with 4-plex iTRAQ 52 (ABI, Framingham, MA, USA) and labelled according to the instructions provided by the manufacturer. All four samples were pooled, peptides separated by reversed-phase liquid chromatography, pH 10, and fractions collected. Details of the procedure are essentially as previously described. 53, 54 Liquid chromatography mass spectrometry. Mass spectrometry was performed on a hybrid LTQ-Orbitrap XL mass spectrometer (ThermoFisher Scientific, Waltham, MA, USA) coupled to an Agilent 1200 HPLC nanoflow system (Agilent Biotechnologies, Palo Alto, CA, USA) via a nanoelectrospray ion source using a liquid junction (Proxeon, Odense, Denmark). Analyses were performed in a data-dependent acquisition mode using a top 6 collision-induced dissociation method for peptide identification alone; or a top 3 high-energy collision-induced dissociation method for peptide identification plus relative quantitation of iTRAQ reporter ions. Details of the LC-MS configuration and mass spectrometer instrument settings are given elsewhere. 54 Data extraction, database search and iTRAQ relative quantitation. Peak list information was extracted from the acquired MS data and searched against the human SwissProt database version v2010.09_20100812 (35 149 sequences, including isoforms as obtained from varsplic.pl) with the search engines MASCOT (v2.2.03, MatrixScience, London, UK) and Phenyx (v2.5.14, GeneBio, Geneva, Switzerland). 55 Details of the protein database search AMPK is a modulator of melanoma oncogene MITF V Borgdorff et al criteria are given elsewhere. 54 iTRAQ relative quantitation analysis was performed with the isobar algorithm. 56 Immunofluorescence and microscopy. Cells were fixed in 4% paraformaldehyde (Merck KGaA, Darmstadt, Germany) for 10 min at room temperature followed by permeabilisation with 90% methanol (Fisher Scientific GmbH, Schwerte, Germany) for 10 min at room temperature. Cells were stained overnight at 4 1C with primary antibody (4 mg/ml) diluted in antibody diluent (Dako, Glostrup, Denmark). The next day, cells were incubated for 2 h at room temperature with AlexaFluor-488-conjugated goat anti-mouse antibody diluted in antibody diluent (Dako). The last phosphate-buffered solution wash step was combined with DAPI (300 nM, Sigma-Aldrich). Cells were imaged on a Zeiss Axiovert 200 M inverted microscope and images were acquired using Zen Software (Manchester, UK).
siRNA transfection. Cells were reverse transfected with 30 nM final concentration siRNA using HiPerfect (Qiagen, Hilden, Germany), siRNAs (Ambion, Austin, TX, USA) siPRKAA1 (s101, s102), siMITF (110566, s8791) and siBcl-2 (s1916, s194310), and negative control siRNA #1 (4390843).
Western blotting. Cells were lysed in Laemmli sample buffer. Cell lysates were sonicated and proteins separated by SDS-PAGE and transferred to Immobilon-P polyvinylidenedifluoride membranes (Millipore). Membranes were blocked with PBST (PBS/0.05% Tween-20 (Sigma-Aldrich)) containing 5% non-fat dry milk (Bio-Rad). Membranes were incubated overnight at 4 1C with primary antibodies diluted in PBST containing 1% non-fat dry milk. After washing with PBST, membranes were incubated for 1 h with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit antibodies diluted in PBST containing 1% non-fat dry milk. Proteins were visualised using ECL Western Blotting Detection Reagents (GE Healthcare Europe, Munich, Germany).
Cell viability assay. Cell viability was assayed by incubating the cells for 4 h with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) followed by formazan solubilisation with DMSO. The OD 492 of the supernatants was determined with an ELISA plate reader (Bender MedSystems GmbH, Vienna, Austria) using OD 620 as the reference wavelength.
Annexin V assay. Cells were collected and resuspended in 1 Â binding buffer (eBioscience, San Diego, CA, USA) after one wash in PBS (Invitrogen). Annexin V-FITC (eBioscience) and PI were added according to the manufacturer's instructions (eBioscience). After 15 min incubation at room temperature, cells were acquired by flow cytometry (FACSCalibur, Heidelberg, Germany) and samples were assessed for the presence of viable cells (annexin V-and PI-negative), early apoptotic cells (annexin V-positive and PI-negative) and late apoptotic cells (annexin V-positive and PI-positive) using CellQuest software (BD Biosciences, Franklin Lakes, NJ, USA).
